Over 700 people are dead. Nearly 1,900 confirmed cases. And there's still no approved vaccine for the strain doing this.
That's the brutal reality unfolding across eastern DRC right now — the worst outbreak the country has ever recorded.
But this week, something shifted.
Most Ebola vaccines target the Zaire strain — the one behind the 2014 West African epidemic.
This outbreak is different.
It's the Bundibugyo strain — first identified in Uganda back in 2007.
No vaccine. No approved treatment. Just supportive care.
For nearly two decades, it sat quietly, waiting for its moment.
Now it's spreading into cities, crossing into Uganda, and pushing health workers to their limit — amid conflict, clinic attacks, and unpaid staff on strike.
This week, scientists at Oxford launched the world's first-ever human trial for a Bundibugyo vaccine.
It's called ChAdOx1 BDBV — built on the same chimpanzee-virus platform behind Oxford's COVID-19 shot.
👉 50 healthy volunteers.
👉 One goal: prove it's safe and triggers the right immune response.
Small trial. Massive symbolic weight.
Here's the part most headlines missed.
Serum Institute of India already manufactured 620,000 doses of this exact vaccine — in just two weeks.
While the science is still early-stage, the manufacturing muscle is already flexed and waiting.
A Phase I trial is step one of many.
Bigger trials. Field testing where the virus actually lives. Regulatory approvals. Mass production.
That's years, not months.
For now, doctors on the ground still have only remdesivir, an experimental antibody, and IV fluids to fight back with.
But for the first time in Bundibugyo's 19-year history, the world finally has a weapon in development.
And that changes everything for the next outbreak, even if it can't save everyone in this one.
That's all for now!
